| Target Molecule | Goserelin |
| Synonyms | Zoladex, ICI 118630, [D-Ser(tBu)6, Azgly10]-LHRH |
| CAS Number | 65807-02-5 (free base); 145781-92-6 (acetate salt) |
| Sequence (3-Letter) | pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH₂ |
| Sequence (1-Letter) | pGlu-HWSY-dSer(tBu)-LRP-AzGly-NH₂ |
| Molecular Formula | C₅₉H₈₄N₁₈O₁₄ |
| Molecular Weight | 1269.41 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98%, ≥99% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Semi-Synthetic C-Terminal Azaglycine Assembly |
| Modification Options | D-serine tert-butyl ether substitution, C-terminal azaglycine incorporation, stable isotope labeling (13C, 15N) |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and structural verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Goserelin (CAS 65807-02-5) is a synthetic decapeptide GnRH agonist featuring an N-terminal pyroglutamate, D-Ser(tBu) at position 6, and a C-terminal azaglycine residue. We target this sequence to supply high-purity reference materials and raw materials for oncology and endocrinology research.
Incorporating azaglycine (where the alpha-carbon is replaced by nitrogen) requires specialized semi-synthetic or solution-phase fragment coupling strategies. Our peptide synthesis platform combines optimized Solid-Phase Peptide Synthesis (SPPS) with targeted fragment condensation, ensuring high-fidelity assembly without epimerization.
Yes. We provide specialized peptide modification services for GnRH analogues. Options include site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), fluorescent or biotin tagging, and the synthesis of specific deletion impurities as analytical reference standards.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Goserelin (CAS 65807-02-5), marketed under the brand name Zoladex, is a synthetic decapeptide operating as a potent gonadotropin-releasing hormone (GnRH) receptor agonist. Defined by the sequence pGlu-HWSY-dSer(tBu)-LRP-AzGly-NH2, it incorporates unnatural amino acid substitutions and a specialized C-terminal azaglycine modification. Synpeptide provides comprehensive custom synthesis solutions for this target molecule, showcasing our technical capabilities in non-standard building block assembly, semi-synthesis, and CDMO manufacturing.
Constructing Goserelin presents severe chemical hurdles due to the presence of bulky tert-butyl ethers on D-serine and the non-standard azaglycine moiety at the C-terminus. Standard SPPS protocols cannot directly incorporate azaglycine without specialized fragment condensation. Our custom peptide synthesis platform resolves these hurdles using hybrid solid- and solution-phase methodologies. By deploying targeted coupling reagents and precise temperature controls, we suppress epimerization and deliver raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
Precise pharmacological profiling and method validation require distinct analytical controls. Through our peptide modification services, we synthesize stable-isotope-labeled Goserelin incorporating heavy amino acids (such as 13C and 15N labeled residues) for quantitative bioanalysis. We also provide terminal modifications and synthesize specific deletion sequences as stability-indicating impurity reference standards.
Transitioning a modified decapeptide from analytical scale to commercial volume demands robust downstream processing. The unique physicochemical profile imparted by the terminal azaglycine requires careful management during preparative HPLC purification and lyophilization. We execute large-scale peptide synthesis for Goserelin utilizing high-capacity preparative HPLC systems and controlled counter-ion exchange. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform acetate salt conversion across all production volumes.
We deliver comprehensive technical support as a fully established peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
